Cargando…

L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling

BACKGROUND: Cancer stem cells (CSC) have been implicated in tumor progression. In ovarian carcinoma (OC), CSC drive tumor formation, dissemination and recurrence, as well as drug resistance, thus contributing to the high death-to-incidence ratio of this disease. However, the molecular basis of such...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giordano, Marco, Decio, Alessandra, Battistini, Chiara, Baronio, Micol, Bianchi, Fabrizio, Villa, Alessandra, Bertalot, Giovanni, Freddi, Stefano, Lupia, Michela, Jodice, Maria Giovanna, Ubezio, Paolo, Colombo, Nicoletta, Giavazzi, Raffaella, Cavallaro, Ugo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513260/ https://www.ncbi.nlm.nih.gov/pubmed/34645505 http://dx.doi.org/10.1186/s13046-021-02117-z

Ejemplares similares

A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing
por: Angiolini, Francesca, et al.
Publicado: (2019)

The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling
por: Zecchini, Silvia, et al.
Publicado: (2011)

Integrated molecular profiling of patient‐derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities
por: Lupia, Michela, et al.
Publicado: (2022)

Different Shades of L1CAM in the Pathophysiology of Cancer Stem Cells
por: Giordano, Marco, et al.
Publicado: (2020)

CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells
por: Lupia, Michela, et al.
Publicado: (2018)

The Pleiotropic Role of L1CAM in Tumor Vasculature
por: Angiolini, Francesca, et al.
Publicado: (2017)

Matrix Gla Protein drives stemness and tumor initiation in ovarian cancer
por: Nieddu, V., et al.
Publicado: (2023)

Antagonistic L1 Adhesion Molecule Mimetic Compounds Inhibit Glioblastoma Cell Migration In Vitro
por: Nagaraj, Vini, et al.
Publicado: (2022)

Endoplasmic reticulum oxidoreductin 1‐alpha deficiency and activation of protein translation synergistically impair breast tumour resilience
por: Varone, Ersilia, et al.
Publicado: (2022)

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
por: Lima, Nadia Carvalho, et al.
Publicado: (2020)

The interplay between NCAM and FGFR signalling underlies ovarian cancer progression
por: Colombo, N, et al.
Publicado: (2011)

Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer
por: Francavilla, Chiara, et al.
Publicado: (2017)

The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin
por: Dellavedova, Giulia, et al.
Publicado: (2023)

The ER stress response mediator ERO1 triggers cancer metastasis by favoring the angiogenic switch in hypoxic conditions
por: Varone, Ersilia, et al.
Publicado: (2021)

Inhibition of N1-Src kinase by a specific SH3 peptide ligand reveals a role for N1-Src in neurite elongation by L1-CAM
por: Keenan, Sarah, et al.
Publicado: (2017)

Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts
por: Guffanti, Federica, et al.
Publicado: (2020)

Ovarian cancer stem cells: still an elusive entity?
por: Lupia, Michela, et al.
Publicado: (2017)

Src is essential for the endosomal delivery of the FGFR4 signaling complex in hepatocellular carcinoma
por: Shin, Ji-Yon, et al.
Publicado: (2021)

The binding of NCAM to FGFR1 induces a specific cellular response mediated by receptor trafficking
por: Francavilla, Chiara, et al.
Publicado: (2009)

Correction: The binding of NCAM to FGFR1 induces a specific cellular response mediated by receptor trafficking
por: Francavilla, Chiara, et al.
Publicado: (2019)

Patient-Derived In Vitro Models of Ovarian Cancer: Powerful Tools to Explore the Biology of the Disease and Develop Personalized Treatments
por: Battistini, Chiara, et al.
Publicado: (2023)

Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging
por: Giordano, Silvia, et al.
Publicado: (2016)

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts
por: Guffanti, Federica, et al.
Publicado: (2018)

The Evaluation of FGFR1, FGFR2 and FOXO1 in Orofacial Cleft Tissue
por: Goida, Jana, et al.
Publicado: (2022)

Src Kinases Are Required for a Balanced Production of IL-12/IL-23 in Human Dendritic Cells Activated by Toll-Like Receptor Agonists
por: Kuka, Mirela, et al.
Publicado: (2010)

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer
por: Yang, Ying, et al.
Publicado: (2020)

Paracrine Fibroblast Growth Factor Initiates Oncogenic Synergy with Epithelial FGFR/Src Transformation in Prostate Tumor Progression()()
por: Li, Qianjin, et al.
Publicado: (2018)

Rhenium N-heterocyclic carbene complexes block growth of aggressive cancers by inhibiting FGFR- and SRC-mediated signalling
por: Domenichini, Alice, et al.
Publicado: (2020)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

Profiling of Epigenetic Features in Clinical Samples Reveals Novel Widespread Changes in Cancer
por: Noberini, Roberta, et al.
Publicado: (2019)

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer
por: Wang, Cong, et al.
Publicado: (2019)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

Label-Free Mass Spectrometry-Based Quantification of Linker Histone H1 Variants in Clinical Samples
por: Noberini, Roberta, et al.
Publicado: (2020)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
por: Cowell, John K., et al.
Publicado: (2021)

FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRC
por: Chen, Xilang, et al.
Publicado: (2023)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

Expression and clinical significance of FGFR1 and FGFR2 in laryngeal squamous cell carcinoma
por: Hu, Mengdie, et al.
Publicado: (2022)

Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Structural and functional characterization of the divergent Entamoeba Src using Src inhibitor-1
por: López-Contreras, Luilli, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5gc79hmif033j3ole8op07fidr